Regenxbio Inc logo

RGNX

Regenxbio Inc

$31.51

Earnings Summary

Revenue
$32.65Mn
Net Profits
$-68.18Mn
Net Profit Margins
-208.82%
PE Ratio
15.81

Highlights

Revenue:

Regenxbio Inc’s revenue jumped 48.17% since last year same period to $32.65Mn in the Q2 2022. On a quarterly growth basis, Regenxbio Inc has generated 46.95% jump in its revenue since last 3-months.

Net Profits:

Regenxbio Inc’s net profit fell -18.29% since last year same period to $-68.18Mn in the Q2 2022. On a quarterly growth basis, Regenxbio Inc has generated 11.14% jump in its net profits since last 3-months.

Net Profit Margins:

Regenxbio Inc’s net profit margin jumped 20.17% since last year same period to -208.82% in the Q2 2022. On a quarterly growth basis, Regenxbio Inc has generated 39.53% jump in its net profit margins since last 3-months.

PE Ratio:

Regenxbio Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 15.81.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Regenxbio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.53
EPS Estimate Current Year
-1.53

Highlights

EPS Estimate Current Quarter:

Regenxbio Inc’s earning per share (EPS) estimates for the current quarter stand at -1.53 - a -15.91% fall from last quarter’s estimates.

EPS Estimate Current Year:

Regenxbio Inc’s earning per share (EPS) estimates for the current year stand at -1.53.

Key Ratios

Key ratios of the Regenxbio Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-1.58
Return on Assets (ROA)
0.09
Return on Equity (ROE)
0.16
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Regenxbio Inc’s earning per share (EPS) fell -16.18% since last year same period to -1.58 in the Q2 2022. This indicates that the Regenxbio Inc has generated -16.18% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regenxbio Inc’s return on assets (ROA) stands at 0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regenxbio Inc’s return on equity (ROE) stands at 0.16.

Dividend Per Share (DPS):

Regenxbio Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-1.32
-1.79
-35.61%
2022-06-30
-1.53
-1.58
-3.27%

Company Information

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Organisation
Regenxbio Inc
Headquarters
Rockville, Maryland, US
Employees
306
Industry
Health Technology
CEO
Kenneth Mills